Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Puretech Health Plc ADR (NQ: PRTC ) 22.27 UNCHANGED Streaming Delayed Price Updated: 11:08 AM EDT, Jul 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 229 Open 22.27 Bid (Size) 9.020 (2) Ask (Size) 36.08 (2) Prev. Close 22.27 Today's Range 22.27 - 22.27 52wk Range 17.08 - 34.00 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial July 23, 2024 From PureTech Health plc Via Business Wire PureTech Health: Completion of Tender Offer & Total Voting Rights June 24, 2024 From PureTech Health plc Via Business Wire Performance YTD -10.92% -10.92% 1 Month -8.16% -8.16% 3 Month -20.15% -20.15% 6 Month -13.08% -13.08% 1 Year -23.34% -23.34% More News Read More PureTech Health: Results of the Tender Offer June 24, 2024 From PureTech Health plc Via Business Wire PureTech Announces Change of Board Role June 20, 2024 From PureTech Health plc Via Business Wire PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team June 18, 2024 From PureTech Health plc Via Business Wire PureTech Health: Results of Annual General Meeting June 13, 2024 From PureTech Health plc Via Business Wire PureTech Health: Result of General Meeting June 06, 2024 From PureTech Health plc Via Business Wire PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company May 29, 2024 From PureTech Health plc Via Business Wire PureTech to Present at the Jefferies Global Healthcare Conference May 23, 2024 From PureTech Health plc Via Business Wire PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection May 21, 2024 From PureTech Health plc Via Business Wire PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share May 20, 2024 From PureTech Health plc Via Business Wire PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting May 09, 2024 From PureTech Health plc Via Business Wire PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments May 07, 2024 From PureTech Health plc Via Business Wire PureTech Announces Annual Results for Year Ended December 31, 2023 April 25, 2024 From PureTech Health plc Via Business Wire PureTech Health: Notice of Results April 18, 2024 From PureTech Health plc Via Business Wire PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis April 16, 2024 From PureTech Health plc Via Business Wire PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers April 11, 2024 From PureTech Health plc Via Business Wire PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions April 09, 2024 From PureTech Health plc Via Business Wire PureTech Proposes $100 Million Capital Return March 19, 2024 From PureTech Health plc Via Business Wire Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion March 18, 2024 From PureTech Health plc Via Business Wire PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia March 13, 2024 From PureTech Health plc Via Business Wire PureTech to Present at Two Upcoming Investor Conferences February 27, 2024 From PureTech Health plc Via Business Wire PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan February 27, 2024 From PureTech Health plc Via Business Wire PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From PureTech Health plc Via Business Wire Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session January 02, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
